ICDX Stock Overview
Focuses on providing online handwritten letter services through its web platform to direct mail marketing companies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Incordex Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$1.30 |
| 52 Week Low | US$1.30 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ICDX | US Commercial Services | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 0.7% |
| 1Y | n/a | 23.9% | 21.5% |
Return vs Industry: Insufficient data to determine how ICDX performed against the US Commercial Services industry.
Return vs Market: Insufficient data to determine how ICDX performed against the US Market.
Price Volatility
| ICDX volatility | |
|---|---|
| ICDX Average Weekly Movement | n/a |
| Commercial Services Industry Average Movement | 6.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ICDX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ICDX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Iurii Abramovici | incordexcorp.com |
Incordex Corp. focuses on providing online handwritten letter services through its web platform to direct mail marketing companies. The company was incorporated in 2020 and is based in Nuneaton, the United Kingdom.
Incordex Corp. Fundamentals Summary
| ICDX fundamental statistics | |
|---|---|
| Market cap | US$8.39m |
| Earnings (TTM) | US$1.33k |
| Revenue (TTM) | US$35.90k |
6,286x
P/E Ratio233.6x
P/S RatioIs ICDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICDX income statement (TTM) | |
|---|---|
| Revenue | US$35.90k |
| Cost of Revenue | US$0 |
| Gross Profit | US$35.90k |
| Other Expenses | US$34.56k |
| Earnings | US$1.33k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00021 |
| Gross Margin | 100.00% |
| Net Profit Margin | 3.72% |
| Debt/Equity Ratio | 164.5% |
How did ICDX perform over the long term?
See historical performance and comparison